



## IMMUNOVIA'S CEO AND BOARD MEMBERS ANNOUNCE INTENTION TO FULLY EXERCISE THEIR TO 3 WARRANTS

**LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm) (the "Company") today announces that its CEO and board members intend to exercise all TO 3 warrants received in the Company's rights issue that was announced on May 20, 2024.**

Immunovia CEO Jeff Borcharding, one of the Company's largest shareholders, intends to exercise all warrants he purchased in the rights issue. In addition, all board members who currently hold TO 3 warrants—Martin Møller, Hans Johansson and Peter Høngaard Andersen—have communicated their intention to fully exercise the TO 3 warrants they hold. In total, holders of 825,834 TO 3 warrants have communicated their intention to fully exercise their TO3 warrants during the exercise period that is currently on-going.

*"Immunovia has a very bright future. The funds from the warrants will finance the commercial launch of the next generation test in Q3 and additional clinical studies to secure payer reimbursement. The board and I are excited to exercise our TO 3 warrants and support these investments."* said Jeff Borcharding, Immunovia's CEO.

One (1) warrant series TO 3 entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 0.24 per share. The exercise period runs until April 15, 2025. Last day of trading in warrants of series TO 3 is April 11, 2025, and the outcome of the exercise of warrants will be published via a press release on or around April 17, 2025.

**For more information, please contact:**

Jeff Borcharding  
CEO and President

[jeff.borcharding@immunovia.com](mailto:jeff.borcharding@immunovia.com)

**Immunovia in brief**

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.

For more information, please visit [www.immunovia.com](http://www.immunovia.com).